In 1996, Winer and collegues demonstrated a reduction in calcium excretion in patients of hypoparathyroidism when treated with  PTH 1-34 (teriparatide) when compared with treatment with calcitriol and calcium. PTH 1–34 (teriparatide) twice daily administered subcutaneoulsy provides a safe and effective alternative to calcitriol therapy and is capable of maintaining normocalcemia without hypercalciuria for at least 3 yr in patients with hypoparathyroidism. PTH 1-34 (teriparatide) has shown to improve the mental and physical health in hypoparathyroid patients.
Hypoparathyroidism future or investigational therapies
Hypoparathyroidism medical therapy
Hypoparathyroidism primary prevention
Pseudohypoparathyroidism medical therapy
Pseudohypoparathyroidism primary prevention
Hypoparathyroidism secondary prevention
Hyperparathyroidism medical therapy
Hyperparathyroidism secondary prevention